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of haematological cancer. The authors hypothe sized that these SNPs could provide a growth advantage for the cells that contain these mutations, which, of course, is depend ent on the genes and of which part of the gene is affected by the poly morphism. For example, increased pro liferation in cancer can be due to a mutation in CDKN2A (also known as p16) that represses the function of CDK6-CDK4, which, in turn, accelerates cell proliferation, a process that does not occur in the context of RA. Okada et al. 1 reported SNPs in CDK4-CDK6 associated with RA; however, whether this polymorphism alters gene expression or protein function is cur rently unknown. Impor tantly, in RA, leuko cytosis is primarily caused by an increase in neutrophils, 9 which might be unrelated to genetic mutations. Investigations of whether these SNPs are associated with syno vial hy perplasia-that is, the prolifera tion and resistance of apoptosis in RA syno vial fibroblasts-would be interest ing. 5 Syno vial fibroblasts are effector cells of joint destruction in RA, 5 the study authors 1 did not mention these cells in their analysis. As such, exploration of the possibility that the described SNPs also have an influence on the aggressive behaviour of RA syno vial fibroblasts is an important new avenue of research. The drugs currently approved for the treatment of RA mostly modulate immune reactions and inflammation. No pharmaceutical compound or biologic agent that targets synovial fibroblasts directly is available yet.
Okada and coworkers 1 proposed that new drugs can be discovered by comparing the RA risk genes with existing data from drug databases. Thus, one of the most important statements of their study is that SNPs associ ated with RA can provide information about possible drug targets. For example, should polymorphisms in CDK4-CDK6 provide a growth advantage to the cells, drugs target ing the products of these genes should be evaluated as a treatment in RA. The first step might be to test such drugs in animal models of arthritis and in mouse models of cartilage destruction (such as the severe combined immuno deficient mouse model of RA). The information from this study 1 could therefore be used by the pharma ceutical industry to reconsider some of their older drugs for RA treatment. An important step forward as a new path for better drug discovery is needed.
Clearly, longitudinal genetic studies in RA are warranted; for example, by using cohorts of patients with early arthritis, one could observe in whom the disease resolves or develops further to chronic arthritis and determine which of the described SNPs can be used as a prognostic marker. Another important issue would be to determine the specificity and the penetrance of the given SNPs; many healthy individuals probably also carried the same polymorphisms, but did not develop arthritis, and these SNPs can also be the object of a longterm popula tion study. Another possibility is to distin guish responders and nonresponders to a drug, for example to antiTNF agents, and to investigate whether the SNPs (for example, those in CFLAR that have been identified by Okada et al. 1 as a target of antiTNF therapies in RA) are different between these patients. Such results could have a direct application in pharmaco genomics 10 and might enable optimization of future therapies for RA.
Some genes that have been associated in the past with susceptibility to RA (such as CTL4A or TNFRSF1B exon 6) are missing in the new list of SNPs reported. 1 This finding might be because these associations are known for Europeans, but has not been con firmed in Asian populations. This issue of neglecting subtypes or variations in ethnicity is intrinsic to the metaanalysis mentioned earlier, and is possibly a major limitation of such studies. Other SNPs known to be asso ciated with RA disease severity were also missing, including those for IL1A2 (exon 5), IL4 variable number tandem repeat poly morphism, and IL10 -1082A>G. All these examples showed that metaanalyses can also lead to a loss of information. In any case, the aim now should be to perform functional analysis of the SNPs rather than to describe further genes associated with RA.
CONNECTIVE TISSUE DISEASES
Systemic sclerosis: beyond limited and diffuse subsets?
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Patients with systemic sclerosis present with varying clinical features, have different responses to therapy, and end up with different outcomes. Categorizing patients improves disease management. A new study now proposes that patients with systemic sclerosis and overlapping features of another connective tissue disease might form a distinct disease subset. Treatment of systemic sclerosis (SSc) can be frustrating, not least because of the remark able disease heterogeneity, with patients having variable clinical manifestations, labora tory and serological findings, compli cations and outcomes. Such vari ability poses 4 Although it remains uncertain whether these two subsets represent truly distinct dis eases or merely different extremes of the disease spectrum, for most patients the dichotomous classification of SSc has with stood the test of time. Numerous studies have confirmed that patients with lcSSc or dcSSc have distinct autoantibody profiles, patterns of organ pathology, disease pro gression and outcomes; 2,3 however, many patients with SSc do not fit neatly into these subclasses, suggesting the need for addi tional categories. In the future, classification of patients with SSc might be done accord ing to an indepth understanding of the genetic and molecular basis of the disease; for now, though, defining new subsets using precise analysis of clinically and laboratory defined characteristics that are common to groups of patients with SSc seems justi fied. The ultimate goal of such subclassifica tion is, of course, to personalize disease manage ment and improve outcomes. A study from Germany now makes a contribution to these efforts by proposing a distinct category of patients with SSc who have features that overlap with another c onnective tissue disease (CTD). 4 Moinzadeh et al. 4 analysed data from 3,240 patients with SSc who enrolled in the 40centre German Network for Systemic Sclero derma, focusing on 342 patients (10% of the total cohort) with an overlap with a CTD. In the absence of established criteria, overlap was defined as having characteristic SSc features concurrently with symptoms or signs suggestive of another CTD. In con trast to patients with dcSSc, classified accord ing to established criteria, 1 patients with SScoverlap had lower modified Rodnan skin scores, and also had less pulmonary fibrosis, less proteinuria and renal crisis, and fewer joint contractures. More over, patients with SScoverlap were less likely to progress to pulmonary fibrosis, pulmo nary hyper ten sion or cardiac dysfunction, such as pal pita tions or conduction distur bances. In sum mary, although intermediate for many cri teria, patients with SScoverlap seem to be more similar to patients with lcSSc than those with dcSSc. Interestingly, musculo skeletal complications, including contractures, synovitis, and muscle weak ness and atrophy, were more common and developed earlier in patients with SSc overlap than in those with either dcSSc or lcSSc. Although the fre quency of overlap syndrome in patients with SSc was lower in this study (10%) than a study in the UK (20%) by Pakozdi et al., 5 over all, the find ings are comparable. Both studies found that patients with SScoverlap were more likely to have limited cutaneous involve ment. The exception seems to be SSc overlap with myositis, in which diffuse or limited cutaneous involvement is equally likely. Of note, the Pakozdi et al. 5 study also showed that the most common CTD coexist ing with SSc was myositis (43%), followed by rheuma toid arthritis (32%), Sjögren's syn drome (17%) and systemic lupus erythe matosus (8%). Unfor tunately, the tem poral relation ship between the onset of SSc and of the overlapping CTD was not examined. Although SScspecific auto anti bodies and CTDspecific auto antibodies, such as antiPM/Scl antibodies, were detected in those with overlapping myo sitis, or antiRo and antiLa anti bodies in those with Sjögren's syn drome, rheumatoid factor was detected in 50% of all patients with SScoverlap (not only those with RA). Not surprisingly, cortico steroids and immuno suppresive drugs were used more commonly in patients with SScoverlap than in those with dcSSc or lcSSc.
A consensus exists on the rationale and usefulness of classifying SSc into limited and diffuse cutaneous subsets. This classi fication helps in risk stratification, predict ing the course of disease and identifying patients appropriate for treatment trials. The existence of an SSc sine subset, com prising patients with SSccharacteristic visceral organ manifestations and auto antibodies, but lacking clinically apparent skin thickening, is also generally accepted. 6, 7 The patients with SSc who fall into this cat egory (~10%) generally have symptoms and signs similar to patients with lcSSc.
Another group of patients with SSc whose disease might constitute a dis tinct subset are those who develop cancer. One study compared eight patients with SSc and antiRNA polymerase III (RNA Pol III) auto antibodies who developed cancer within 2.5 years of SSc diagnosis with eight patients with SSc and either anti centromere or anti topoisomerase 1 (TOP1) auto antibodies who developed cancer a median of 14.2 years after diagnosis of SSc. 8 Genetic analyses of tumour samples revealed somatic missense mutations or loss of hetero zygosity in POLR3A (which encodes RNA Pol III A subunit) in five of the www.nature.com/nrrheum NEWS & VIEWS eight patients who tested positive for anti RNA Pol III autoantibodies. By contrast, no somatic mutations in the genes encoding major centromere auto antigen B (CENPB) or TOP1 were found in patients with SSc who tested positive for anti centromere or antiTOP1 autoanti bodies. The authors speculate that, in patients with antiRNA Pol III auto antibodies, cancer might trigger SSc via antitumour im munity. 9 Whether the presence of antiRNA Pol III anti bodies in patients with SSc who develop cancer defines a distinct SSc subset, akin to a para neoplastic syndrome, remains to be estab lished. Along with similar observations from other studies, Moinzadeh et al. 4 make a case that SScoverlap is a separate disease subset. We are, therefore, now faced with five or six clinically defined and moreorless distinct subsets of SSc (Figure 1 ). Whilst current clinical practice increasingly makes use of this classification scheme, further studies are needed to establish and confirm the valid ity of these SSc subsets, compare and con trast their genetic and pathophysio logical features and evaluate their utility in clinical decisionmaking.
We anticipate that, in the future, precise classi fication of patients with SSc will be based on an integrated 'systems' strat egy. A molecular classification of SSc that incor porates traditional clinical variables com bined with information from serum auto antibody testing and highthroughput analytical approaches, such as functional gen omics, proteomics or metabolo mics, might pro vide substantial added insight into dis ease hetero geneity, and have implica tions for a personalized medicine approach to patient management. Already, genomewide expres sion profiling of biopsyobtained skin sam ples from patients with SSc has revealed intriguing molecular hetero geneity that is uncoupled from clinicallydefined sub classes (Figure 1 ). For instance, Milano et al. 9 identified five gene signatures in SSc skin samples that define distinct molecular sub sets. Pilot studies have provided 'proof ofconcept' that molecular sub classifica tion of patients with SSc might facilitate the selec tion of targeted therapies and improve out comes. 10 Using advanced classification approaches in clinical trials will be neces sary for validating preliminary observa tions and defining their predictive value and clinic al utility.
Moinzadeh et al. 4 propose that we should con sider SScoverlap as a distinct disease subset. Recognizing the 10-20% of patients with SSc who fall within this subset should help in choosing targeted therapeutic strat egies. Further research to define the dis tinct genetic and pathophysiological characteristic s of SSc subsets is urgently needed. 
